Patents Assigned to Betta Pharmaceuticals Co., Ltd.
-
Patent number: 11845762Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.Type: GrantFiled: August 29, 2022Date of Patent: December 19, 2023Assignee: BETTA PHARMACEUTICALS CO., LTD.Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
-
Publication number: 20230391779Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions comprising such compounds and use thereof. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.Type: ApplicationFiled: August 17, 2021Publication date: December 7, 2023Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Xiaofeng XU, Jinheng GAO, Hongfei RONG, Xizhen SONG, Jie CHEN, Xiangyong LIU, Hongling SHEN, Jing GUO, Dan YAN, Hong LAN, Lieming DING, Jiabing WANG
-
Publication number: 20230339882Abstract: A compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation diseases. The compounds of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.Type: ApplicationFiled: July 22, 2021Publication date: October 26, 2023Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Hao WU, Wenmao WU, Ling LI, Zhan ZHANG, Feng WANG, Ding YUAN, Yunfei WU, Qiang CHEN, Han HAN, Jing GUO, Hong LAN, Lieming DING, Jiabing WANG
-
Publication number: 20230192705Abstract: Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.Type: ApplicationFiled: June 10, 2021Publication date: June 22, 2023Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Bang FU, Zhongxin SUN, Xiaofeng XU, Wei REN, Yinlong LI, Ling LI, Lieming DING, Jiabing WANG
-
Publication number: 20230133169Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.Type: ApplicationFiled: October 13, 2020Publication date: May 4, 2023Applicant: BETTA PHARMACEUTICALS CO., LTDInventors: Xiangyong LIU, Changyong QIU, Guolong DU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Lieming DING, Jiabing WANG
-
Publication number: 20230131025Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.Type: ApplicationFiled: February 8, 2021Publication date: April 27, 2023Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Xiangyong LIU, Changyong QIU, Mengqiang LIU, Xiaodong SONG, Qichao SHEN, Guolong DU, Haitong SHENG, Lieming DING, Jiabing WANG
-
Publication number: 20230053342Abstract: An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthesis method therefor and use thereof.Type: ApplicationFiled: November 4, 2020Publication date: February 23, 2023Applicant: BETTA PHARMACEUTICALS CO., LTDInventors: Houxian ZU, Xizhen SONG, Kai CHEN, Xiangyong LIU, Jie CHEN, Yajing BIAN, Lieming DING, Jiabing WANG
-
Publication number: 20230022091Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.Type: ApplicationFiled: August 29, 2022Publication date: January 26, 2023Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Yan XU, Xiaofeng XU, Jiabing WANG, Lieming DING
-
Patent number: 11466013Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.Type: GrantFiled: June 6, 2019Date of Patent: October 11, 2022Assignee: Betta Pharmaceuticals Co., LtdInventors: Hao Wu, Wei Gu, Xiaojing Tang, Wei Wang, Bo Zhan, Dongjie Feng, Yongxin Ke, Zhongyan Chen, Yifei Shen, Wenmao Wu, Xintao Zhao, Hong Lan, Jiabing Wang, Lieming Ding
-
Patent number: 11466034Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.Type: GrantFiled: December 20, 2018Date of Patent: October 11, 2022Assignee: Betta Pharmaceuticals Co., Ltd.Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
-
Patent number: 11365196Abstract: An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like.Type: GrantFiled: February 27, 2018Date of Patent: June 21, 2022Assignee: Betta Pharmaceuticals Co., Ltd.Inventors: Xiaofeng Xu, Jiabing Wang, Lieming Ding, Xiangyong Liu
-
Publication number: 20220041583Abstract: Provided herein is compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.Type: ApplicationFiled: September 12, 2019Publication date: February 10, 2022Applicant: BETTA PHARMACEUTICALS CO., LTDInventors: Yiqian WANG, Yao ZHANG, Bang FU, Jiabing WANG
-
Publication number: 20210261552Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.Type: ApplicationFiled: June 6, 2019Publication date: August 26, 2021Applicant: Betta Pharmaceuticals Co., LTDInventors: Hao WU, Wei GU, Xiaojing TANG, Wei WANG, Bo ZHAN, Dongjie FENG, Yongxin KE, Zhongyan CHEN, Yifei SHEN, Wenmao WU, Xintao ZHAO, Hong LAN, Jiabing WANG, Lieming DING
-
Publication number: 20210261546Abstract: The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.Type: ApplicationFiled: June 21, 2019Publication date: August 26, 2021Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Yiqian WANG, Chunhui ZHANG, Jiabing WANG, Lieming DING
-
Patent number: 11053238Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.Type: GrantFiled: December 22, 2017Date of Patent: July 6, 2021Assignee: BETTA PHARMACEUTICALS CO., LTD.Inventors: Yiqian Wang, Jiabing Wang, Lieming Ding
-
Publication number: 20210130353Abstract: An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. AA %%% Formula (I).Type: ApplicationFiled: February 27, 2018Publication date: May 6, 2021Applicant: Betta Pharmaceuticals Co., Ltd.Inventors: Xiaofeng XU, Jiabing WANG, Lieming DING, Xiangyong LIU
-
Patent number: 10577364Abstract: The compound of Formula I, the crystalline form thereof, and methods of preparing and using them are provided.Type: GrantFiled: July 20, 2016Date of Patent: March 3, 2020Assignee: BETTA PHARMACEUTICALS CO., LTDInventors: Shaojing Hu, Wei Long, Liufeng Zhou, Zhiguo Xu, Fei Wang
-
Patent number: 10059688Abstract: Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.Type: GrantFiled: September 1, 2017Date of Patent: August 28, 2018Assignee: BETTA PHARMACEUTICALS CO., LTD.Inventors: Shaojing Hu, Xiangyong Liu, Jinlong Bai, Wei Long
-
Publication number: 20180186788Abstract: The compound of Formula I, the crystalline form thereof, and methods of preparing and using them are provided.Type: ApplicationFiled: July 20, 2016Publication date: July 5, 2018Applicant: BETTA PHARMACEUTICALS CO., LTDInventors: Shaojing HU, Wei LONG, Liufeng ZHOU, Zhiguo XU, Fei WANG
-
Publication number: 20180009782Abstract: Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.Type: ApplicationFiled: September 1, 2017Publication date: January 11, 2018Applicant: BETTA PHARMACEUTICALS CO., LTD.Inventors: Shaojing HU, Xiangyong Liu, Jinlong Bai, Wei Long